Lotus Pharmaceuticals (OTCMKTS:LTUS – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Lotus Pharmaceuticals and ProKidney, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lotus Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| ProKidney | 2 | 1 | 4 | 1 | 2.50 |
ProKidney has a consensus target price of $7.40, indicating a potential upside of 345.78%. Given ProKidney’s stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Lotus Pharmaceuticals.
Risk and Volatility
Insider & Institutional Ownership
51.6% of ProKidney shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Lotus Pharmaceuticals and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lotus Pharmaceuticals | N/A | N/A | N/A |
| ProKidney | -7,725.20% | N/A | -18.83% |
Earnings and Valuation
This table compares Lotus Pharmaceuticals and ProKidney”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lotus Pharmaceuticals | N/A | N/A | -$30,000.00 | N/A | N/A |
| ProKidney | $890,000.00 | 563.13 | -$68.99 million | ($0.52) | -3.19 |
Lotus Pharmaceuticals has higher earnings, but lower revenue than ProKidney.
Summary
ProKidney beats Lotus Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Lotus Pharmaceuticals
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Receive News & Ratings for Lotus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lotus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
